2000, Kinsel & Capoferri 2008 , Schneider et al. 2011 , De Bruyckere et al. 2015 . According to a clinical study in humans, soft tissue volume grafting is responsible for 43% of the final volume and therefore serves as a major contributor to an optimal final outcome in single-tooth implant sites (Schneider et al. 2011) . Based on scientific evidence autogenous grafts are considered to be the gold standard for soft tissue volume augmentation rendering an increase ranging between 1.7 and 3.2 mm over time (Thoma et al. 2009 (Thoma et al. , 2014 . Major disadvantages and limitations associated with the use of autogenous grafts, are the harvesting procedure and variations in quality and quantity of tissue that is available for grafting. To overcome these drawbacks and to standardize grafting procedures, soft tissue substitutes were introduced in the past. These devices were predominantly used to increase the width of keratinized tissue, for ridge preservation and recession coverage (Wei et al. 2000 , Jepsen et al. 2013 , Jung et al. 2013 , Schmitt et al. 2013 . In terms of a more extensive volume increase, these devices cannot be recommended rendering a limited soft tissue volume gain only , Simion et al. 2012 . Therefore, a volume stable cross-linked collagen matrix (VCMX) was developed recently and evaluated in a number of in vitro and preclinical studies (Mathes et al. 2010 , 2011a . The VCMX demonstrated favourable mechanical and biological properties, enhancing connective tissue formation within the collagen matrix body, undergoing simultaneous remodelling process and partial degradation (Thoma et al. 2015) . In terms of soft tissue volume increase, the VCMX provided a similar gain in ridge width based on histological and volumetric outcome measures when applied to chronic ridge defects (Thoma et al. , 2011a . Clinically, the number of patients treated with dental implants increases and due to aesthetic needs, soft tissue volume augmentation might be a desired therapy. Currently, no data are available for the use of soft tissue substitutes to increase soft tissue volume at implant sites and histological data for VCMX placed on the surface of implants and regenerated peri-implant bone are missing.
The aim of this study was, therefore, to test whether soft tissue augmentation with a VCMX leads to an increase in ridge width at dental implant sites similar to those obtained by an autogenous subepithelial connective tissue graft (SCTG).
Material and Methods

Study design
This study was designed as a randomized controlled experimental study and conducted in accordance with the OECD Good Laboratory Practice regulations, ENV/MC/ CHEM (98) 17, with the European Good Laboratory Practice regulations, 2004/10/EC Directive and with the United States Food and Drug Administration Good Laboratory Practice regulations, 21 CFR 58. The protocol was approved by the local ethical committee of NAMSA (Lyon, France) on September 9, 2013. Twelve adult male beagle dogs (about 2 years old), weighing 11 AE 3 kg, were kept in a purposedesigned room for experimental animals and fed a soft diet during the entire study period.
Animal preparation and medication
The dogs were fasted for food [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ; Aguettant, Lyon, France) were administered for each hemi-mandible. An overview on the schedule of the study is displayed in Fig. 1 . Fig. 1 . Overview of the study schedule.
Extractions and implant placement
Following elevation of a mucoperiosteal flap on the lingual and buccal side between M2 and P1, all mandibular mesial roots of P3, P4 and M1 were extracted and the buccal bone plates removed ( Fig. 2A) . The distal roots of each P3, P4 and M1 were root canal treated according to a previously described procedure . A two-piece dental implant (Straumann BoneLevel, 3.3 mm 9 8 mm; Institut Straumann AG, Basel, Switzerland) was placed in the area of the mesial root of P3, P4 and M1 with the implant shoulder at the level of the lingual bone crest (Fig. 2B) . The buccal peri-implant dehiscence and infrabony defects were regenerated with demineralized bovine bone mineral [Bio-Oss Ò (0.25-1 mm); Geistlich Pharma AG, Wolhusen, Switzerland] (Fig. 2C) . A native collagen membrane (BioGide Ò ; Geistlich Pharma AG, Wolhusen, Switzerland) was applied to cover the augmented area (Fig. 2D ). Following rinsing with sterile saline and releasing incisions within the periosteum, primary wound closure was obtained with non-resorbable sutures (GoreTex suture; Gore, Flagstaff AZ, USA) (Fig. 2E ).
Soft tissue augmentation
Soft tissue augmentation surgeries were performed on one side of the mandible at 25 weeks and repeated on the contra-lateral side at 29, 42 or 45 weeks (both post implant placement) (Fig. 3A) . For that purpose, sulcular incisions were made around P1 and P2, the remaining roots of P3, P4 and M1 and partial-thickness flaps elevated, thereby preparing a pouch on the buccal side of the implants. Subsequently, three treatment modalities were randomly applied to the defect sites according to a computergenerated randomization list:
• Volume stable cross-linked collagen matrix made of porcine collagen (VCMX) (Fibro-Gide; Geistlich Pharma AG, Wolhusen, Switzerland).
• Autogenous SCTG.
• Sham-operated site (control).
The VCMX is designed as a matrix for submerged healing and to serve as a replacement for the autogenous SCTG ). The matrix is characterized by a loose network, is cross-linked and made of porcine collagen. It combines the stability of cross-linked collagen membranes (Brunel et al. 1996) and the favourable tissue integration of non-cross-linked collagen membranes (Thoma et al. 2011b ), but does not have a membrane function. The VCMX (dimension: 10 mm 9 7.5 mm 9 5 mm) was positioned in the pouch underneath the elevated buccal flap. The VCMX was stabilized with a horizontal mattress suture connecting it to the lingual flap (Dafilon Ò 5-0; B. Braun Melsungen AG, Melsungen, Germany) (Fig. 3B1) . The SCTG was harvested from the lateral part of the palatal vault . Fatty, and glandular tissue, as well as remnants of the epithelium were removed, resulting in a dimension (thickness) similar to the VCMX. Compression with a sterile gauze and 3-4 single sutures (Dafilon Ò 5-0; B. Braun Melsungen AG) were used to reposition the epithelial coverage at the palatal donor site. The SCTG was then positioned in the buccal pouch under the elevated flap and immobilized using a horizontal mattress suture connecting it to the (Fig. 3B2 ). In control sites no further augmentation was performed (Fig. 3B3) . Subsequently, in all sites, periosteal releasing incisions were made to allow for a tension-free primary wound closure using one horizontal mattress suture and 4-5 single sutures (Dafilon Ò 5-0; B. Braun Melsungen AG) (Fig. 3C ). Suture removal was performed 14 days later and the sites were macroscopically inspected.
Sacrifice
At 1, 2 and 6 months post soft tissue augmentation, euthanasia was performed by a lethal injection of a barbiturate (Dolethal Ò , V etoquinol S.A., Paris, France). The hemimandibles were sampled en bloc and fixed in 4% neutral-buffered formalin for histopathological analysis.
Histological preparation
After initial fixation, the hemi-mandibles were dissected into individual blocks with a band saw (one block per site) and fixed again in 4% neutral-buffered formalin. After complete fixation, the sites were dehydrated in alcohol solutions of increasing concentration, cleared in xylene and embedded in polymethylmetacrylate. One central buccolingual cross section through the dental implant was performed by a microcutting and grinding technique (approximately 40-50 lm thick; Donath & Breuner 1982) . The histological slides were stained with a modified polychromatic stain (Paragon) for qualitative, semi-quantitative and quantitative histopathological analysis.
Descriptive histology
The histological sections were analysed by light microscopy (Nikon Eclipse 80i, Nikon, Tokyo, Japan objectives: 92, 910, 920, 940 and 960) equipped with a colour image analysing system Tribvn Ò (Tribvn, Chatillon, France). A qualitative and semi-quantitative evaluation of the tissue effects was performed in adaptation to ISO 10993 6 and in compliance with the standard nomenclature of the International Society for Stereology (Exner 1987) .
Histomorphometric measurements
The histomorphometric outcomes were assessed according to Fig. 4 . For that purpose, the borders of the prepared pouch underneath the buccal flap augmented with the VCMX, the SCTG or left empty (control) were defined. A horizontal line (bucco-lingual axis) was drawn at the top of the lingual crest, perpendicularly to the dental implant (green line in Fig. 4) . A vertical line (corono-apical axis) was then drawn perpendicularly to this horizontal line, at the level of the top of the threads of the implant (orange line in Fig. 4 ). Four additional lines (blue) were drawn perpendicularly to the vertical line at four different levels (1.5, 3.5, 5.5 and 7.5 mm) below the horizontal line. The ridge width (bucco-lingual axis) was measured along these horizontal lines (green and blue lines) for implant, bone marrow, bone substitute material, bone, pouch with the VCMX, SCTG or empty control (=aug-mented soft tissue thickness) and native soft tissue (Fig. 4) .
Statistical analysis
Data were summarized in terms of means and standard deviations. The local tissue effects and performance were compared among groups and time-points as follows: VCMX versus SCTG and control; SCTG versus control; for each group, comparison between the different time periods (1, 2 and 6 months). The local tissue effects were evaluated based on comparison of the semi-quantitative histopathological inflammatory parameters. No statistical analysis was performed for these parameters. The performance evaluation was based on the semi-quantitative histopathological evaluation and the quantitative histomorphometric evaluation. For that purpose, a statistical analysis was conducted (5% risk) with a statistical software (Software SPSS, IBM, Zurich, Switzerland version 19.0; SPSS Inc.) for the augmented soft tissue thickness.
Results
Clinical and macroscopic findings
The dogs remained healthy and neither systemic complications nor local intolerances at the augmented sites occurred during the entire study period. Some soft tissue dehiscences or delayed wound healing, however, occurred after extractions and implant placement (one side in two dogs) as well as after soft tissue augmentation surgeries (one side in two dogs). These observations were not correlated with any treatment group and all sites healed without further treatment.
Descriptive histology
In general, inconsistent signs of osseointegration of the bone graft particles were observed. Frequent signs of fibrous encapsulation and/or loss of the bone graft particles were noted. A moderate to marked grade horizontal and/or vertical bone regeneration was observed up to 6 months irrespective of the groups. This often led to buccal implant surfaces being covered by soft tissues. In some sites the native collagen membrane persisted over time and was still visible up to 6 months.
Volume stable cross-linked collagen matrix
At 1 month, a slight to moderate infiltration of macrophages and lymphocytes and a limited number of plasma cells was observed (Fig. 5A) . The VCMX was integrated and slightly to moderately degraded (Fig. 5B) . A slight to moderate grade of soft tissue augmentation and vertical bone growth was observed. At 2 months, the VCMX network was integrated, moderately degraded and slightly infiltrated by macrophages, lymphocytes and plasma cells. A slight soft tissue augmentation and a moderate grade of vertical bone growth were observed. At 6 months, no signs of local inflammation were visible anymore. A null to slight soft tissue augmentation and a moderate to marked grade of vertical bone growth were evident. In addition, discrete signs of mineralization were noted in one out of eight sites. The VCMX was completely integrated and markedly to severely degraded (Fig. 5C ).
Subepithelial connective tissue graft
At 1 month, no significant local inflammation was observed (Fig. 5D) . The SCTG was integrated, remodelled and degraded to a moderate to marked degree. A slight soft tissue augmentation and a marked grade of vertical bone growth occurred. One site demonstrated discrete signs of mineralization. From 2 months on, no local inflammation or mineralization was observed (Fig. 5E ). The SCTG was not clearly identifiable and was considered fully degraded at 2 months. No obvious signs of soft tissue augmentation were evident, whereas a marked grade of bone growth had occurred. At 6 months, no soft tissue augmentation, but a moderate to marked grade of bone growth was evident (Fig. 5F ). 
Control
The tissues were healed at 1 month. Soft tissue augmentation, local inflammation and signs of mineralization were not observed at any time-point. Bone formation, however, increased over time up to a marked grade at 6 months (Fig. 5G ).
Histomorphometric outcomes (horizontal soft tissue thickness)
All data are displayed in Table 1 and Appendix S1. Other than reported, no statistically significant differences were observed between the groups for any of the outcomes measures (Table 2 ; p > 0.05).
In general, the augmented soft tissue thickness for VCMX and SCTG were highest at the level 0 mm at 1 month and decreased to the level 7.5 mm up to 6 months. Control sites revealed no relevant augmented soft tissue thickness at any level and any time-point (range: 0.07-0.66 mm).
At 1 month, VCMX and SCTG showed overall higher values of augmented soft tissue thickness at all apico-coronal ridge height levels compared to the control group. At 1.5 and 3.5 mm, the VCMX group had significantly more soft tissue gain compared to the control group (p = 0.011; p = 0.019), whereas the SCTG group had significantly more soft tissue gain at 0 and 1.5 mm compared to the control group (p = 0.019; p = 0.012) ( Table 2) .
At 2 months, the VCMX and SCTG groups showed overall higher values of augmented soft tissue thickness at all apico-coronal ridge height levels compared to the control group, even though VCMX and SCTG values decreased when compared to 1 month. The differences between VCMX and control were significant at 3.5 mm (p = 0.030) ( Table 2) .
At 6 months, VCMX and SCTG demonstrated a higher gain of augmented soft tissue thickness at all apico-coronal ridge height levels compared to the control group. Again, the overall number of VCMX and SCTG had decreased from 2 months. At 3.5 mm, the VCMX group yielded significantly higher values of augmented soft tissue thickness compared to the control group (p = 0.015). At 5.5 mm, the SCTG group yielded significantly higher values compared to control group (p = 0.025) ( Table 2.) Other than reported, none of the differences in augmented soft tissue thickness were statistically significantly different between the groups (p > 0.05) ( Table 2) .
Discussion
The present experimental study revealed that (i) soft tissue volume increase could be obtained using VCMX and SCTG, (ii) control sites did not show any gain in soft tissue thickness, (iii) augmented soft tissues underwent major remodelling processes over time and, (iv) these remodelling and degradation processes lead to a decrease in the augmented soft tissue thickness between 2 and 6 months for VCMX and SCTG.
The stability and thickness of augmented soft tissues is considered to be a contributing factor for the success of dental implants and helps to facilitate the choice of the reconstructions (Jung et al. 2008 , Brito et al. 2014 . This is based on clinical data that demonstrate soft tissue surgeries contribute to more than 40% of the final horizontal/buccal volume with minimal changes up to 1 year (Schneider et al. 2011) , as well as the critical threshold value of the mucosal thickness being 2 mm (Jung et al. 2007 ). In case <2 mm of buccal mucosal thickness is present, the use of a metal abutment may lead to a greyish discoloration of the mucosa, whereas all-ceramic reconstructions are more favourable in terms of aesthetics (Jung et al. 2008 , van Brakel et al. 2011 ). This in turn means that a certain mucosal thickness may be desired to leave more freedom in the choice of the reconstruction material. Autogenous SCTGs are still considered to be the gold standard and data on soft tissue substitutes for soft tissue volume augmentation are limited to preclinical data or limited to devices not primarily intended to be used for volume increase (Thoma et al. 2014) . The outcomes of this study revealed a similar and successful increase in mucosal thickness at implant sites at 1 and 2 months. This is in line with previous data comparing the same two treatment modalities (VCMX and SCTG) for soft tissue volume augmentation in chronic ridge defects (Thoma et al. 2011a) . In that study, a volume increase at 1 month and stability of the augmented region up to 3 months was documented. That study also revealed that both soft tissue grafts underwent remodelling and degradation processes. For the VCMX, more bone formation and a slightly higher loss of ridge width (in terms of soft tissue) was observed. A different study design was chosen for the present experimental trial. Immediate implant placement with simultaneous GBR (Guided Bone Regeneration) was performed. Even though a healing time of 25 and 45 weeks was initiated prior to soft tissue augmentation -and in contrast to previous data with chronic ridge defects -a more acute situation was present. These sites probably underwent changes in terms of maturation and regeneration of the hard tissue augmentation, which might have contributed to a more reactive environment for the soft tissue grafts on top. In addition, as identified on the histological slides, the GBR procedure was not as successful as expected. A major part of the applied biomaterials was lost (probably due to encapsulation within the soft tissues) or displaced more apically. This resulted in implant surfaces being exposed to the soft tissues. As clearly visible on the histological slides, VCMX and SCTG were placed in part on these exposed implant surfaces without underlying bony support (Fig. 5) . These two reasons could explain, why both soft tissue grafts, VCMX and SCTG, underwent more extensive remodelling and degradation processes and demonstrated only a limited increase in augmented soft tissue thickness at 6 months. Moreover, in the previously published study , the augmented soft tissues (both VCMX and SCTG) had a higher initial thickness (augmented thickness: 10 mm, uncompressed). This is in contrast to this study, where SCTG and VCMX were not folded and had a thickness of roughly 50% (5 mm) compared to the previous experimental trial. Still, remnants of the transplanted SCTG and of the matrix body (VCMX) could be identified at the last 
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Measures are depicted for the three groups SCTG (subepithelial connective tissue graft); VCMX (volume stable cross-linked collagen matrix) and sham-operated site (control) at five different levels perpendicular to the implant axes (0, 1.5, 3.5, 5.5, 7.5 mm). Mean, standard deviations (SD) and medians were calculated with a confidence interval (CI) of 95%.
sacrifice time-point (6 months). This is, for VCMX, in line with a previous study in rats (Thoma et al. 2015) . In that study, VCMX was placed in subcutaneous pouches and followed up to 6 months. Similar to this study, remnants of the matrix could be observed, but the thickness of the VCMX had been decreased. Another explanation for the minimal soft tissue thickness, slightly higher than control sites, could be that the ridge was augmented outside the bony envelope. It has been speculated that in cases where bone regeneration is attempted by overcontouring the ridge (bone regeneration outside the bony envelope), the obtained final ridge width is suboptimal with an increased rate of buccal bone loss or an only limited gain (Park et al. 2009 , Garaicoa et al. 2015 . In terms of soft tissues, one might speculate that the minimal increase, observed at 6 months, might be due to the augmentation outside of the bony envelope. SCTGs had been used in the past to augment chronic ridge defects and controlled up to 5 years post insertion of the final fixed dental prosthesis (Sanz Martin et al. 2016) . The study revealed stable soft tissues and a minimal decrease in height and volume over 5 years. Control sites without soft tissue grafting demonstrated the same stability as SCTG sites. This long-term stability might reflect that once augmented soft tissues are stimulated by the pontic of a fixed dental prosthesis, these sites might undergo less volumetric changes.
The descriptive histology and semi-quantitative analyses demonstrated that the augmented SCTG integrated and subsequently remodelled and degraded to a marked grade without a significant inflammation at 1 month. At the same time, bone formation had taken place underneath the SCTG. Data of a previous study with a similar set-up (Thoma et al. 2011a ), but chronic ridge defects that were augmented, revealed a similar limited inflammatory reaction. The borders to the underlying bone, however, were distinct. This might be explained by the chronic defects, whereas in this study, remodelling and maturation processes from the underlying GBR materials were ongoing and resulted in a less distinct border towards the bone. From 2 months on in this study, the SCTG was not clearly identifiable and degraded to a marked grade leaving almost no augmented soft tissue left at 6 months. The native soft tissue, however, increased during the entire study period in all groups. This observation could have in part compensated the loss of the augmented area and might be explained by difficulties to assed the border between augmented and native soft tissue. The observation that soft tissues demonstrate spontaneous thickening and can compensate for missing hard tissue on the buccal side of dental implants has been reported in clinical studies (Benic et al. 2012 , Chappuis et al. 2015 , Kuchler et al. 2016 . In terms of collagen-based soft tissue substitutes and membranes, a variety of preclinical and clinical studies have been published in the past. Based on these experiments, degradation, tissue integration and angiogenesis were predominantly influenced by the composition of the membranes/ matrices with more favourable biological attributes for native noncross-linked collagen-based materials compared to controls (Rothamel et al. 2004 , Schwarz et al. 2006 . For VCMX, previous data revealed ongoing long-term remodelling processes up to 6 months in a mouse model (Thoma et al. 2015) and up to 3 months in a canine model (Thoma et al. 2011a) . At 1 month, in both studies, the VCMX was fully integrated without clear distinction to the surrounding tissues and thereby demonstrated favourable biological properties enhancing connective tissue formation. Similar to previous data, a marked degradation was observed up to the 6-month timepoint. The VCMX were partially replaced by newly formed connective tissue, but left only a minimal soft tissue thickness. In contrast to SCTG sites, VCMX sites demonstrated a slight to moderate infiltration of inflammatory cells at 1 and 2 months, but not at 6 months. Tissue integration of (non)cross-linked collagen membranes and matrices has been investigated previously. In an ectopic mouse model, two prototype VCMX were implanted in subcutaneous pouches. The inflammatory reaction at 3 and 6 weeks was limited (Thoma et al. 2012) . In contrast, similar to this study, a significantly elevated number of inflammatory reactions in the adjacent soft tissues was observed in a clinical study using a cross-linked membrane (Becker et al. 2009 . In this study, histological slides were analysed for mineralization within the augmented soft tissues, thereby assessing the biocompatibility and local tolerance of the soft tissue substitute (VCMX) and the transplanted autogenous grafts (SCTG). For both VCMX and SCTG, mineralization was observed in one site only at one time-point only. This underlined that the grafting materials could be safely used without hampering tissue integration and elicited biocompatibility.
From a clinical point of view, this study indicated that both VCMX and SCTG, could be used for soft tissue augmentation at implant sites. Clinicians need to be aware of ongoing hard and soft tissue remodelling processes that could change the tissue architecture. It remains unknown, however, how the augmented soft tissues would behave if pressure or stimulation is applied by reconstructions once dental implants are loaded or FDPs (Fixed Dental Prostheses) inserted in these areas. Future research is needed to determine an optimal time-point to start conditioning of augmented soft tissues (with VCMX and SCTG) at implant sites.
Conclusion
The cross-linked volume-stable collagen matrix and the SCTG rendered a similar gain in ridge width at sites where implants with simultaneous guided bone regeneration had been placed. The ridge width was predominantly increased at 1 and 2 months for VCMX and SCTG sites. The augmented areas underwent continuous and enhanced remodelling processes, both, on the hard and soft tissue level. At 6 months, most of the VCMX network and the augmented SCTG had been degraded and/or replaced leaving only a minimal increase in soft tissue thickness. VCMX sites demonstrated a slight to moderate infiltration with inflammatory cells during the first 2 months, whereas in SCTG sites, no inflammation was present. Adverse tissue reactions such as local intolerance or issues with biocompatibility were negligible for VCMX and SCTG. Both VCMX and SCTG can be used for soft tissue augmentation at dental implant sites, however, rendering short-term gain in ridge width only.
